Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OCS-05+SoC administration · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| OCS-05 +SoC (corticosteroid) IV administration | DRUG | OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days |
| Placebo + SoC (corticosteroid) IV administration | OTHER | Placebo + SoC (corticosteroid) IV administration for 5 consecutive days |
OCS-05+SoC administration refers to the investigational small molecule OCS-05 given together with standard of care, which in this program is a corticosteroid, for the treatment of optic neuritis. It is being developed by Oculis Holding AG as a neurology asset and has been studied in a Phase 2 trial.
OCS-05+SoC administration is being studied for optic neuritis, an inflammatory condition affecting the optic nerve. The Phase 2 program evaluated the combination of OCS-05 with standard of care corticosteroid treatment in patients with optic neuritis. It is investigational and has not been approved for any indication.
OCS-05+SoC administration is being developed by Oculis Holding AG, which trades under the ticker OCS. The company is the sponsor of the clinical program evaluating OCS-05 together with standard of care corticosteroid treatment in optic neuritis.
OCS-05+SoC administration has completed a Phase 2 clinical trial in optic neuritis. It is an investigational therapy and is not approved by the FDA. No active trials of this combination are currently listed, and the completed study enrolled 36 patients.
OCS-05+SoC administration was evaluated in the Phase 2 trial NCT04762017, titled OCS-05 in Patients With Optic Neuritis. That study is completed and enrolled 36 patients. It was an uncontrolled trial without randomization or double blinding, and it did not select patients by biomarker.